Merck Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing

Contributed by: Business Wire

Logo

Images

Merck operators monitoring viral vector production in a bioreactor in Merck's Carlsbad, California manufacturing facility. (Photo: Business Wire)

Business Wire embedded0

Tags

Health

Genetics

Research

Pharmaceutical

Science

Biotechnology

Acquisition

More Like This

ViroCell Biologics Completes Oversubscribed Financing

ViroCell Biologics Signs Master Services Agreement With Prominent NCI-Designated Cancer Center

ViroCell and Great Ormond Street Hospital Poised to Unlock Clinical Trial ‘Backlog’ Following MHRA Manufacturing Approval

Ajinomoto Co., Inc. to Acquire Forge Biologics for $620 Million1

Merz Enters Asset Purchase Agreement With a US-Based Biotech Company

Vect-Horus Enters Exclusive License Agreement with Novo Nordisk to Develop Targeted Therapeutics

Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases

ViroCell Biologics to Host Panel Event at 2024 Cell & Gene Meeting on the Mesa